EA200200302A1 - Полиморфная соль - Google Patents

Полиморфная соль

Info

Publication number
EA200200302A1
EA200200302A1 EA200200302A EA200200302A EA200200302A1 EA 200200302 A1 EA200200302 A1 EA 200200302A1 EA 200200302 A EA200200302 A EA 200200302A EA 200200302 A EA200200302 A EA 200200302A EA 200200302 A1 EA200200302 A1 EA 200200302A1
Authority
EA
Eurasian Patent Office
Prior art keywords
relates
polymorphic salt
migraine
published
medicine
Prior art date
Application number
EA200200302A
Other languages
English (en)
Other versions
EA004510B1 (ru
Inventor
Артур Бентли
Саймон Арнольд Ховард-Филд
Рональд Джеймс Огилви
Original Assignee
Пфайзер Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пфайзер Инк. filed Critical Пфайзер Инк.
Publication of EA200200302A1 publication Critical patent/EA200200302A1/ru
Publication of EA004510B1 publication Critical patent/EA004510B1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Настоящее изобретение касается кристаллической полиморфной формы соединения формулы (I), характеризующейся картиной рентгеновской дифракции порошка, полученной с использованием излучения меди К-альфа(λ=0,15046 нм), которая показывает основные пики при 9,28; 10,38; 11,37; 12,40; 16,84; 17,46; 17,53; 17,78; 17,98; 19,48; 20,70; 21,29; 21,45; 22,21; 22,64; 23,08; 25,20 и 25,79. Изобретение также относится к способу получения названной формы, к фармацевтической композиции, содержащей ее, и к ее использованию в медицине, в частности, для лечения состояний, при которых показан агонист 5-HTрецептора, например мигрени.Отчет о международном поиске был опубликован 2002.03.07.
EA200200302A 1999-09-28 2000-09-14 Полиморфная форма гемисульфата 3-(n-метил)-2(r)-пирролидинилметил-5-(2-фенилсульфонилэтил)-1h-индола EA004510B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9922963.5A GB9922963D0 (en) 1999-09-28 1999-09-28 Polymorphic salt
PCT/IB2000/001305 WO2001023377A2 (en) 1999-09-28 2000-09-14 Polymorphic salt

Publications (2)

Publication Number Publication Date
EA200200302A1 true EA200200302A1 (ru) 2002-10-31
EA004510B1 EA004510B1 (ru) 2004-04-29

Family

ID=10861767

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200200302A EA004510B1 (ru) 1999-09-28 2000-09-14 Полиморфная форма гемисульфата 3-(n-метил)-2(r)-пирролидинилметил-5-(2-фенилсульфонилэтил)-1h-индола

Country Status (50)

Country Link
US (1) US6369094B1 (ru)
EP (1) EP1233960B1 (ru)
JP (1) JP3795395B2 (ru)
KR (1) KR100479897B1 (ru)
CN (1) CN1155594C (ru)
AP (1) AP2004A (ru)
AR (1) AR025779A1 (ru)
AT (1) ATE246185T1 (ru)
AU (1) AU779580B2 (ru)
BG (1) BG65161B1 (ru)
BR (1) BR0014272A (ru)
CA (1) CA2379572C (ru)
CO (1) CO5180567A1 (ru)
CR (1) CR6561A (ru)
CU (1) CU23200A3 (ru)
CZ (1) CZ2002971A3 (ru)
DE (1) DE60004262T2 (ru)
DK (1) DK1233960T3 (ru)
DZ (1) DZ3254A1 (ru)
EA (1) EA004510B1 (ru)
EE (1) EE200200171A (ru)
EG (1) EG24143A (ru)
ES (1) ES2200911T3 (ru)
GB (1) GB9922963D0 (ru)
GE (1) GEP20043365B (ru)
GT (1) GT200000159A (ru)
HK (1) HK1048628B (ru)
HR (1) HRP20020270B1 (ru)
HU (1) HUP0202821A3 (ru)
IL (1) IL147154A (ru)
IS (1) IS2162B (ru)
MA (1) MA26821A1 (ru)
MX (1) MXPA02003311A (ru)
MY (1) MY121170A (ru)
NO (1) NO321936B1 (ru)
NZ (1) NZ516093A (ru)
OA (1) OA12024A (ru)
PA (1) PA8498901A1 (ru)
PE (1) PE20010662A1 (ru)
PL (1) PL354960A1 (ru)
PT (1) PT1233960E (ru)
SI (1) SI1233960T1 (ru)
SK (1) SK3982002A3 (ru)
TN (1) TNSN00187A1 (ru)
TR (1) TR200200804T2 (ru)
TW (1) TWI265926B (ru)
UA (1) UA72272C2 (ru)
WO (1) WO2001023377A2 (ru)
YU (1) YU2602A (ru)
ZA (1) ZA200202406B (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214711B2 (en) * 1998-12-23 2007-05-08 Neurotherapeutics Pharma Llc Method of treating migraine headache without aura
US20060025387A1 (en) * 1998-12-23 2006-02-02 Cytoscan Sciences Llc Compositions and methods for the treatment of disorders of the central and peripheral nervous systems
US8008283B2 (en) * 1998-12-23 2011-08-30 Neurotherapeutics Pharma, Inc. Methods and compositions for the treatment of neuropsychiatric disorders
US8722668B2 (en) * 1998-12-23 2014-05-13 Daryl W. Hochman Methods and compositions for the treatment of neuropathic pain and neuropsychiatric disorders
GB0018968D0 (en) * 2000-08-02 2000-09-20 Pfizer Ltd Particulate composition
GB0312478D0 (en) * 2003-05-30 2003-07-09 Pfizer Ltd Improved process
US7132549B2 (en) 2003-05-30 2006-11-07 Pfizer Inc. Process
CA2588465C (en) * 2004-12-03 2013-10-01 Merck & Co., Inc. Pharmaceutical composition containing an anti-nucleating agent
JP2009511629A (ja) * 2005-10-17 2009-03-19 ニューロセラピューティクス ファーマ, インコーポレイテッド 中枢神経系疾患の調節に有用な利尿薬様化合物類似体
KR100814109B1 (ko) * 2006-01-09 2008-03-14 한국생명공학연구원 로다닌 유도체, 이의 제조방법 및 이를 유효성분으로함유하는 약학적 조성물
TWI394753B (zh) * 2006-03-17 2013-05-01 Otsuka Pharma Co Ltd 新穎替妥牟拉(tetomilast)晶體
WO2010116386A2 (en) * 2009-04-08 2010-10-14 Biophore India Pharmaceuticals Pvt. Ltd. Novel polymorph of eletriptan hydrobromide and process for the preparation thereof
PL2493312T3 (pl) 2009-10-26 2022-01-03 Merck Sharp & Dohme Corp. Kompozycje farmaceutyczne w postaci ciała stałego zawierające inhibitor integrazy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559129A (en) 1990-10-15 1996-09-24 Pfizer Inc Indole derivatives
US5559246A (en) 1990-10-15 1996-09-24 Pfizer Inc. Indole derivatives
RO111767B1 (ro) * 1990-10-15 1997-01-30 Pfizer Derivati de indol, procedee si intermediari pentru prepararea acestora, compozitii farmaceutice si metoda pentru tratarea unor afectiuni
US5545644A (en) 1990-10-15 1996-08-13 Pfizer Inc. Indole derivatives
US5578612A (en) 1990-10-15 1996-11-26 Pfizer Inc. Indole derivatives
US5607951A (en) 1990-10-15 1997-03-04 Pfizer Inc Indole derivatives
GB9417310D0 (en) * 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
US5998462A (en) * 1996-12-16 1999-12-07 Allelix Biopharmaceuticals Inc. 5-alkyl indole compounds
US6166025A (en) * 1997-07-03 2000-12-26 Pfizer Inc. Pharmaceutical compositions containing eletriptran hemisulphate and caffeine

Also Published As

Publication number Publication date
CO5180567A1 (es) 2002-07-30
TNSN00187A1 (fr) 2005-11-10
HK1048628B (zh) 2004-10-21
WO2001023377A3 (en) 2002-03-07
GT200000159A (es) 2002-03-20
GB9922963D0 (en) 1999-12-01
KR20020032627A (ko) 2002-05-03
TWI265926B (en) 2006-11-11
ZA200202406B (en) 2003-05-28
CR6561A (es) 2005-04-04
HUP0202821A2 (hu) 2003-01-28
EP1233960B1 (en) 2003-07-30
WO2001023377A2 (en) 2001-04-05
SI1233960T1 (en) 2003-12-31
JP2003510318A (ja) 2003-03-18
AP2002002457A0 (en) 2002-06-30
IL147154A0 (en) 2002-08-14
IS6223A (is) 2002-01-08
AU6721300A (en) 2001-04-30
AU779580B2 (en) 2005-01-27
AR025779A1 (es) 2002-12-11
EE200200171A (et) 2003-06-16
DZ3254A1 (fr) 2001-04-05
PT1233960E (pt) 2003-11-28
GEP20043365B (en) 2004-05-10
EG24143A (en) 2008-08-06
DE60004262T2 (de) 2004-01-22
MA26821A1 (fr) 2004-12-20
PA8498901A1 (es) 2004-02-07
TR200200804T2 (tr) 2002-07-22
DE60004262D1 (de) 2003-09-04
KR100479897B1 (ko) 2005-03-31
JP3795395B2 (ja) 2006-07-12
HRP20020270B1 (en) 2004-04-30
CU23200A3 (es) 2007-04-06
CA2379572C (en) 2006-11-14
NO20021525D0 (no) 2002-03-26
SK3982002A3 (en) 2003-05-02
NZ516093A (en) 2005-01-28
MXPA02003311A (es) 2002-10-04
ATE246185T1 (de) 2003-08-15
YU2602A (sh) 2004-11-25
OA12024A (en) 2006-04-19
DK1233960T3 (da) 2003-10-27
AP2004A (en) 2009-06-10
NO20021525L (no) 2002-03-26
IL147154A (en) 2005-11-20
EA004510B1 (ru) 2004-04-29
IS2162B (is) 2006-11-15
US6369094B1 (en) 2002-04-09
PE20010662A1 (es) 2001-06-23
UA72272C2 (ru) 2005-02-15
BR0014272A (pt) 2002-05-21
HUP0202821A3 (en) 2003-12-29
CA2379572A1 (en) 2001-04-05
PL354960A1 (en) 2004-03-22
CN1364166A (zh) 2002-08-14
ES2200911T3 (es) 2004-03-16
BG106240A (en) 2002-07-31
WO2001023377A9 (en) 2002-03-28
MY121170A (en) 2005-12-30
NO321936B1 (no) 2006-07-24
EP1233960A2 (en) 2002-08-28
HRP20020270A2 (en) 2003-06-30
BG65161B1 (bg) 2007-04-30
CN1155594C (zh) 2004-06-30
CZ2002971A3 (cs) 2003-04-16
HK1048628A1 (en) 2003-04-11

Similar Documents

Publication Publication Date Title
RU2213089C2 (ru) Моноциклические бензамиды производных 3- или 4-замещенного 4-(аминометил)пиперидина, способы их получения, фармацевтическая композиция, способ ее приготовления, производное карбоновой кислоты
EA200200302A1 (ru) Полиморфная соль
Essaber et al. Synthesis of new tri-and tetraheterocyclic systems: 1, 3-dipolar cycloaddition of nitrilimines on 2, 7-dimethyl-4-phenyl-3H-1, 5-benzodiazepine
AP1407A (en) Novel ß Crystalline Form of Perindopril Tert-Butylamine Salt, Preparation Method, And Pharmaceutical Compositions Containing Same.
ES2123149T3 (es) Derivados de perhidroisoindol como antagonistas de la substancia p.
IE59901B1 (en) Piperidine derivative, its preparation, and its use as medicament
BG63630B1 (bg) Кристална хемикалциева сол на [r-(r*,r*)]-2-(4-флуорофенил)-бета,делта-дихидрокси-5-(1-метилeтил)-3-фенил-4-[(фениламино)карбонил]-1н-пирол-1-хептанова киселина (аторвастатин)
BR0211201A (pt) Composto, processo para a preparação desse composto, sua utilização, composição farmacêutica que compreende o mesmo e método para o tratamento de uma enfermidade em um mamìfero
RU94044671A (ru) Применение непептидных антагонистов рецептора тахикинина
AP1452A (en) Novel y crystalline form of perindopril tert-butylamine salt preparation method, and pharmaceutical compositions containing same.
EA200300519A1 (ru) Соединения производных бензотиофена, способ их получения и применения
EA200200774A1 (ru) Новые соединения, обладающие гиполипидемической, гипохолестеринемической активностью, способ их получения и содержащие их композиции
HU199425B (en) Process for producing alpha-alkyl-/4-amino-3-quinolinyl/-methanols and 1-square brackets open 4-/aralkylamino/-3-quinolinyl square brackets closed -alkanones, as well as pharmaceutical compositions comprising such compounds as active ingredient
ES8800182A1 (es) Un metodo para producir derivados de 1,5-benzoxazepina
DE69918465D1 (de) Sulfonamidhydroxamate
IE62936B1 (en) Arylthiazolylimidazoles as 5ht3 antagonists
DE69207301T2 (de) Substituierte 3-Piperazinylalkyl 2,3-Dihydro-4H-1,3-Benzoxazin-4-One, deren Herstellung und Verwendung in Heilkunde
EP1122252A1 (en) Nitrogenous fused heterocycle compounds, process for the preparation thereof and agents containing the same
PL294705A1 (en) Method of obtaining 2-hydroxy-2-phenylamine compounds or their bioprecursor substances or pharmaceutically admissible salts
DE60317632T2 (de) 2-oxazolamine und ihre verwendung als 5-ht2b-rezeptor-antagonisten
DE60206068D1 (de) Aralkyltetrahydropyridine, deren herstellung und pharmazeutische zusammensetzungen, die diese enthalten
Aatif et al. Synthesis of novel [1, 2, 4] triazolo [3, 4-d][1, 5] benzodiazepinones derivatives by 1, 3-dipolar cycloaddition
PE20010216A1 (es) Procedimiento para preparar derivados de 10,11-metanobenzosuberano
RU2005102821A (ru) Новые производные циклоалкандиона, способ их получения и их применение в фармацевтике
RU1838311C (ru) Способ получени 2-(3-пиридил)тетрагидротиапиранкарботиоамид-2-оксида-1(1R, 2R)

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU